Oncology

Lung cancer
#European Commission #Lung cancer #Monoclonal antibodies #Oncology

European Commission approves Tevimbra for small cell lung cancer

The European Commission has approved Tevimbra (tislelizumab), in combination with etoposide and platinum chemotherapy, as a first-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC).  The new indication is based on results of RATIONALE-312 study, which demonstrated statistically significant overall survival benefit for patients treated with Tevimbra… Read More

#News #Regulatory

#Financing #Immunotherapy #Oncology #Ovarian cancer #Scandinavia

TILT Biotherapeutics closes $25 million Series B financing

Finnish biotechnology company TILT Biotherapeutics (Tiltbio) has raised $25.6 million (€22.6 million) in a Series B financing.  The financing will support a Phase II clinical trial of Tiltbio’s lead product, TILT-123, in patients with platinum-resistant epithelial ovarian cancer, a Phase Ib trial in melanoma in combination with TILs and other… Read More

#Business & Investment #News

Gastrointestinal tract
#Cell and gene therapy #Cell therapy #CRISPR #Gastrointestinal #Gene editing #Oncology

CRISPR TIL therapy shows early success in GI cancers

Researchers at the University of Minnesota have completed a first-in-human clinical trial testing a CRISPR/Cas9 gene-editing technique to help the immune system fight advanced gastrointestinal (GI) cancers.   The results, published in Lancet Oncology, show encouraging signs of safety and potential… Read More

#Cancer Research #Editor's Choice #News

#Cancer research #Drug discovery #Events #Oncology #Webinar

Webinar: Unpacking the latest developments in cancer research

This free webinar at 3pm BST on 12 June, hosted by DDW and sponsored by Scale Biosciences, will see experts and thought-leaders from the cancer research sector discuss where innovation is occurring and what the challenges are to overcome for drug discovery projects in the oncology field. … Read More

Webinar date:
Sponsored by Scale Biosciences
#News

#Cancer research #Drug discovery #Events #Oncology

Unpacking the latest developments in cancer research

This free webinar, hosted by DDW and sponsored by Scale Biosciences, sees experts and thought-leaders from the cancer research sector discuss where innovation is occurring and what the challenges are to overcome for drug discovery projects in the oncology field. Presenters include Roy Maute, CEO and co-founder of Pheast Therapeutics,… Read More

Webinar date:
Sponsored by Scale Biosciences
#Webinars

Indonesian and Scottish flags
#Cancer Research UK #Collaboration #Indonesia #Oncology #Scotland

Indonesia-Scotland cancer research partnership signed

The Ministry of Health of the Republic of Indonesia and the CRUK Scotland Institute have entered into a landmark partnership to advance cancer research, build capacity in cancer care, and support evidence-based health policies through the signing of a Memorandum of Understanding (MoU).  Dr Susanti Susanti, an… Read More

#Cancer Research #News

#Cancer research #Oncology #Solid tumours

New DDW Highlights podcast: 12 May 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Our highlights this week demonstrate a variety of approaches to cancer treatment, including a… Read More

#News

#Cancer research #Oncology #Solid tumours

This week in drug discovery (5-9 May) 

News round-up for 5-9 May by DDW Senior Digital Content Editor Diana Spencer. Our highlights this week demonstrate a variety of approaches to cancer treatment, including a BTK inhibitor, macrophage checkpoint inhibitor, and antibody-drug conjugates, at various stages of development. The top stories:… Read More

#News

AAV virus
#AAV #Biotech #Collaboration #Oncology

Partners advance virus-like particle platform for liver cancer

Hovione and Firstgene Life Sciences have announced a strategic collaboration to advance Hovione’s proprietary virus-like particle drug delivery platform for the targeted treatment of Hepatocellular Carcinoma (HCC), a therapeutic indication developed by Firstgene.  Under the terms of the collaboration, Hovione will grant Firstgene an exclusive license to its proprietary novel… Read More

#Business & Investment #News

#AACR #AACR 2025 #Cancer research #Oncology

New DDW Highlights podcast: 7 May 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. With the American Association of Cancer Research (AACR) Annual Meeting taking place from 25-30 April,… Read More

#News

Antibody drug conjugate
#AACR #Antibody drug conjugate (ADC) #Oncology #Solid tumours #SOTIO

ADCs show best-in-class potential for treating solid tumours

SOTIO Biotech has presented preclinical data on two of its leading antibody-drug conjugate (ADC) candidates, SOT109 and SOT106, demonstrating strong anti-tumour activity and favourable tolerability profiles across multiple tumour models.  The data shared at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, IL supports… Read More

#Cancer Research #News

#Bioinformatics #Enedra Therapeutics #Funding #Oncology #Precision medicine #Start-ups

Enedra secures financing for precision cancer therapies

Enedra Therapeutics has secured venture financing and non-dilutive funding through UKRI’s Innovate UK Future Economy Investor Partnerships programme to support the development of next-generation precision therapies for advanced, genetically heterogeneous cancers.  The financing round was supported by KU Leuven’s Centre for Drug Design and Discovery (CD3), o2h Ventures, and follow-on… Read More

#Business & Investment #News #Start-up Zone

Map of Europe
#AstraZeneca #European Commission #Lymphoma #Oncology #Phase III trial

Calquence plus chemoimmunotherapy approved in the EU

AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been approved in the European Union (EU) for previously untreated mantle cell lymphoma (MCL).  It is approved in patients who are not eligible for autologous stem cell transplant.  The approval by the European Commission was based on positive results from… Read More

#News #Regulatory

Liver cancer
#Macrophages #Oncology #Phase I trial #Pheast Therapeutics #Solid tumours

First patient receives anti-CD24 macrophage checkpoint inhibitor

Pheast Therapeutics has treated the first patient in its Phase I clinical trial evaluating PHST001, an anti-CD24 macrophage checkpoint inhibitor, in patients with advanced solid tumours.  The study will enrol up to 80 patients with advanced relapsed and/or refractory solid tumours.  The study’s primary objectives… Read More

#Cancer Research #News #Trending News

#AACR #AACR 2025 #Cancer research #Oncology

This week in drug discovery (28 April – 2 May) 

News round-up for 28 April – 2 May by DDW Senior Digital Content Editor Diana Spencer. With the American Association of Cancer Research (AACR) Annual Meeting taking place from 25-30 April, the DDW news desk has been inundated with the latest advances in cancer drug discovery, so here… Read More

#News

#Artificial intelligence (AI) #Cancer research #Data management #Diversity #Oncology #Quantum computing

Opportunities and challenges in oncology

DDW Editor Reece Armstrong takes a look at some of the recent activity in cancer research and examines where the biggest opportunities are in oncology.  In January this year, researchers from the University of Toronto (UoT) and Insilico Medicine published a paper detailing how quantum computing combined with generative AI… Read More

#Cancer Research #Exclusive Content #Trends & Analysis